Stockscreener 앱 받기
6.88
12.58%
-0.99
시간 외 거래:
6.79
-0.09
-1.31%
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat
Published on: 2026-03-02 22:13:30 - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union
RNAC Should I Buy - Intellectia AI
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN
Published on: 2026-02-25 09:47:28 - baoquankhu1.vn
Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget
What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru
Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews
Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn
Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru
Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru
FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus
Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews
Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat
Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - Sahm
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews
Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn
Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn
Aug Mood: Is Cartesian Therapeutics Inc stock a top performer YTDJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Pharma News: Does Cartesian Therapeutics Inc have declining or rising EPSQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-01-22 19:08:46 - mfd.ru
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Risk Check: Is Cartesian Therapeutics Inc benefiting from interest rate changes2025 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
Why Cartesian Therapeutics Inc. stock is a value investor pickMarket Growth Summary & Reliable Price Action Trade Plans - ulpravda.ru
Cartesian Therapeutics (RNAC): Needham Raises Price Target to $4 - GuruFocus
Myasthenia Gravis Market Positioned for Accelerated - openPR.com
Cartesian Therapeutics highlights recent progress and outlines 2026 outlook - marketscreener.com
Cartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile Dermatomyositis - Quiver Quantitative
Cartesian Therapeutics Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire
What momentum indicators show for Cartesian Therapeutics Inc. stockQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Is Cartesian Therapeutics Inc. stock resilient to inflationJuly 2025 Final Week & Growth Focused Stock Pick Reports - Улправда
Cartesian Therapeutics (NASDAQ:RNAC) CFO Sells $72,230.62 in Stock - MarketBeat
Is Cartesian Therapeutics Inc. stock supported by innovation pipelineWeekly Stock Report & Free Technical Pattern Based Buy Signals - ulpravda.ru
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 354.71% Potential Upside in the Biotech Frontier - DirectorsTalk Interviews
Is Cartesian Therapeutics Inc. stock a buy before product launches2026 world cup usa national team quarterfinals defensive leaders transition play group prediction preview - Улправда
Cartesian Therapeutics, Inc.Common Stock (NQ: RNAC - FinancialContent
What analysts say about Cartesian Therapeutics Inc 1S70 stockPortfolio Allocation Tips & Small Investment Wealth Growth - earlytimes.in
3.69%
0.68%
자본화:
|
볼륨(24시간):